Alimera Sciences

Retinal Disease
is Our Focus

Moving the back of the eye to the forefront
of research and development.

Learn more about our goals »

ILUVIEN: Investigational Treatment for DME

ILUVIEN® fluocinolone acetonide intravitreal insert 0.19mg

Investigational Treatment For DME

Providing the diabetic patient with a low-drug exposure, sustained-release treatment for Diabetic Macular Edema.

Learn more about how ILUVIEN works »

Diabetes is the leading cause of new cases of blindness in adults

DIABETES and
VISION LOSS

Diabetes is the leading cause of new cases of blindness in adults.

Learn how Alimera Sciences is creating reliable, effective treatments for diabetic retinopathy »

Latest News

View All Recent News »

Alimera Sciences Receives Complete Response Letter From FDA for ILUVIEN®

November 11, 2011 -- Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a complete response letter...

Read More »

Alimera Sciences to Present at November Conferences

November 07, 2011 -- Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that management will be attending the following...

Read More »

Alimera Sciences Reports Third Quarter 2011 Financial Results

November 03, 2011 -- Alimera Sciences, Inc. ...

Read More »